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Abstract The M-band is the prominent cytoskeletal
structure that cross-links the myosin and titin filaments in
the middle of the sarcomere. To investigate M-band
alterations in heart disease, we analyzed the expression of
its main components, proteins of the myomesin family, in
mouse and human cardiomyopathy. Cardiac function
was assessed by echocardiography and compared to the
expression pattern of myomesins evaluated with RT-PCR,
Western blot, and immunofluorescent analysis. Disease
progression in transgenic mouse models for dilated car-
diomyopathy (DCM) was accompanied by specific M-band
alterations. The dominant splice isoform in the embryonic
heart, EH-myomesin, was strongly up-regulated in the
failing heart and correlated with a decrease in cardiac
function (R = -0.86). In addition, we have analyzed the
expressions of myomesins in human myocardial biopsies
(N = 40) obtained from DCM patients, DCM patients
supported by a left ventricular assist device (LVAD),
hypertrophic cardiomyopathy (HCM) patients and controls.
Quantitative RT-PCR revealed that the EH-myomesin
isoform was up-regulated 41-fold (P \ 0.001) in the DCM
patients compared to control patients. In DCM hearts
supported by a LVAD and HCM hearts, the EH-myomesin
expression was comparable to controls. Immunofluorescent
analyses indicate that EH-myomesin was enhanced in a
cell-specific manner, leading to a higher heterogeneity of
the myocytes’ cytoskeleton through the myocardial wall.
We suggest that the up-regulation of EH-myomesin
denotes an adaptive remodeling of the sarcomere cyto-
skeleton in the dilated heart and might serve as a marker
for DCM in mouse and human myocardium.
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Introduction
Dilated cardiomyopathy (DCM), is a major and increasing
cause of morbidity and mortality including sudden cardiac
death, and affects approximately 40 out of 100,000 people,
of which 30–50% have a genetic origin [20]. Characterized
by left ventricular dilation and systolic dysfunction, DCM
often leads to terminal heart failure requiring cardiac
transplantation [13]. Most identified mutations affect genes
encoding cytoskeletal proteins suggesting the impairment
of force transmission [28] or failing of the cardiomyocyte
stretch sensor machinery [22] as possible mechanisms
underlying this disorder. However, also the mutations in
sarcomeric proteins [20] and nuclear membrane protein
lamin A/C encoding genes [17, 32] may cause DCM. In
addition, there is growing evidence that acquired factors
such as autoimmunity, virus-induced chronic inflammation
and impaired protein quality control may also contribute to
the DCM development and heart failure [21, 38]. While the
cause of the disease might be identified in many cases, the
pathophysiological mechanisms that control the progres-
sion to the irreversible ventricular remodeling and heart
failure are largely unknown [14]. The analysis of sarco-
meric cytoskeleton alterations, in particular of the M-band,
might provide important clues to understand the patho-
logical mechanisms in DCM.
The basic functional unit of the heart muscle is the
sarcomere, which contracts due to sliding of myosin over
actin filaments. The sarcomere cytoskeleton provides the
scaffold for contractile filaments and includes three basic
structural elements: the Z-disk and the M-band, two
transverse structures anchoring the thin and thick filaments,
and the elastic titin filaments connecting these longitudi-
nally (Fig. 1a). The M-band is believed to organize the
thick filament lattice and plays an important role in sar-
comere mechanics [3]. Its important structural elements are
three closely related proteins of the myomesin family
(Fig. 1b). Myomesin (or myomesin-1) [16] appears to be
an essential component of the sarcomere as it was found in
all studied vertebrate muscles. Myomesin makes anti-par-
allel dimers which are believed to cross-link the myosin
filaments in the M-band, a role analogous to a-actinin in
the Z-disk [23]. Myomesin interaction with the titin
M-band portion [30] might be crucial for the mechano-sensing
and signaling functions mediated by the stretch-activated
Ser/Thr-kinase domain of titin [3, 24, 34]. Myomasp/
LRRC39 was characterized recently as a novel M-band
component associated with mechano-sensitive signaling
pathways [40]. Interestingly, the knockdown of myomasp
leads to a significant down-regulation of myomesin-1 and
myomesin-2 expression and decreases contractile force in
heart muscle. The EH-myomesin splice isoform (see
Fig. 1b), generated by inclusion of an elastic segment [35]
in the center of the molecule, is the main M-band com-
ponent in the embryonic heart of higher vertebrates [1] and
is expressed in slow skeletal fibers of mice [4]. Similarly,
two other members of the myomesin protein family,
M-protein and myomesin-3, show muscle-type specific
Fig. 1 Sarcomere cytoskeleton
and M-band protein
components. a Scheme of the
sarcomere depicting the main
components of the sarcomeric
cytoskeleton (M-band, Z-disk
and titin). b Myomesin (white),
M-protein (gray) and
myomesin-3 (dark gray) are
composed of immunoglobulin-
like domains (ellipses) and
fibronectin type 3 domains
(rectangles). The alternatively
spliced EH-domain (EH) and
the N-terminal domains are
intrinsically unstructured
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expression patterns. M-protein is found in adult heart and
fast skeletal muscle [15], myomesin-3 appears in inter-
mediate speed fibers of skeletal muscle but not in mouse
heart at any developmental stage [36]. This indicates that
the M-band is a dynamic structure which adapts to the
contractile parameters of a given muscle by varying the
proportion of EH-myomesin and the level of M-protein and
myomesin-3. Accordingly, this cytoskeletal system might
represent a valid biomarker for pathological processes in
the heart such as cardiomyopathy.
Aiming to establish the general relationships between the
M-band alterations and heart function, we have designed a
study comprising the analysis of mouse models and human
myocardial biopsies. We first studied the M-band protein
alterations in the hearts of two transgenic mouse models: the
muscle LIM protein knockout mouse (MLP-KO), a well-
established model for DCM [5] and a mouse with stabilized
b-catenin in the heart (b-catenin Dex3), which progressively
develops a severe DCM phenotype resulting in heart failure
and premature death [19]. The disease progression was
monitored by echocardiography and compared to the
expression of myomesins. Human samples obtained from
cardiac surgery patients were analyzed in the same way.
Methods
Animal breeding and maintenance
Transgenic knock-in mice expressing Cre recombinase
under control of the myosin light chain 2v promoter [9]
were bred with b-catenin exon 3 floxed mice [18] to gene-
rate animals with a stabilization of the protein restricted to
the ventricular myocardium (MLC2vCre/wt;b-catenin exon
3 flox/flox) referred to later as b-catenin cDex3. Genotyping
for Cre and b-catenin alleles was performed as described
[25]. MLP-deficient mice were described earlier [5]. Age-
matched WT controls were used for all experiments.
Maintenance and animal experimentation are conforming
to the Swiss Federal Veterinary Office guidelines.
Echocardiography
Transthoracic echocardiography was performed by a blin-
ded investigator using a 30-MHz probe and the Vevo 770
Ultrasound machine (VisualSonics). The rodent was placed
under 1% isoflurane anesthesia via a nose cone and posi-
tioned on a 37C heated surface. The eyes of the animals
were protected from drying by lubricating ophthalmic gel.
Under anesthesia, the following parameters were moni-
tored: heart rate, body temperature (with rectal probe),
ECG trace, and respiration. The hair was removed with an
epilatory cream (deemed suitable for use in rodents).
The echocardiography images were obtained by placing
warmed gel on the rodent, and the ultrasound probe actu-
ally never touched the animal itself due to the gel interface.
The average anesthetic period lasted 10 min.
Echocardiographic analysis (all measured after the
mouse was anesthetized) included basic left ventricular
function parameters, cardiac output, stroke volume, left
ventricular dimensions, and transvalvular flow indices. The
study protocol was approved by the Swiss Federal Veter-
inary Office.
Antibodies
Monoclonal mouse anti-myomesin antibodies (clone B4)
[16], polyclonal rabbit anti-EH-myomesin (pR-anti-moEH
for mouse) [4] and anti-myomesin-3 antibodies (pR-anti-
My3-N) [36] were generated as described. The antibodies
against human EH-myomesin (pR-anti-huEH) were gene-
rated in our laboratory (see details below). Monoclonal
mouse anti-M-protein antibodies (clone AA259, IgA)
were generously donated by Prof. D. O. Fu¨rst (Potsdam,
Germany). Monoclonal antibodies against sarcomeric
a-actinin (clone EA-53) and polyclonal antibodies against
all actin isoforms (A2066) were obtained from Sigma-
Aldrich (Buchs, Switzerland). Monoclonal antibodies
against b-catenin were obtained from Transduction Lab
(cat.no. 610154) and antibodies against N-cadherin from
Invitrogen (Zymed, 33-3900). Polyclonal antibodies against
b-catenin were obtained from Sigma-Aldrich (C2206) and
used for immunoblotting.
Horseradish peroxidase-conjugated anti-rabbit Igs
(Calbiochem, San Diego, USA) and anti-mouse IgA (Sigma-
Aldrich) were used as secondary antibodies for immuno-
blotting. Fluorescein isothiocyanate (FITC)-conjugated
goat-anti-mouse IgA (Sigma-Aldrich), Cy3-conjugated
goat-anti-mouse IgG (Fab-fragments) and Cy5-conjugated
goat-anti-rabbit antibodies were used as secondary anti-
bodies for immunofluorescence staining (Jackson Immuno
Research, West Grove, PA, USA).
Generation of antibodies against human EH-myomesin
Total RNA of human embryonic heart was isolated using
the SV Total RNA isolation system (Promega, Wallisellen,
Switzerland). The EH-fragment of human myomesin was
amplified by RT-PCR on approximately 1 lg of total RNA
with the Access RT-PCR system (Promega) using a stan-
dard RT-PCR protocol suggested by the manufacturer.
Primers used for the amplification were derived from the
human myomesin sequence (see ‘‘RT-qPCR’’). The seg-
ment was cloned into BamHI and EcoRI sites of the bac-
terial expression plasmid pGEX-2T (Amersham Pharmacia
Biotech, Otelfingen, Switzerland) and expressed in the
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E. coli strain BL-21 Star (Invitrogen, Basel, Switzerland).
The soluble glutathione S-transferase fusion protein was
purified from crude bacterial lysate by affinity chroma-
tography on glutathione-agarose (Sigma). Antibodies
against human EH-myomesin (anti-huEH) were generated
by immunizing adult rabbits with this recombinant EH-
fragment fused to glutathione S-transferase.
SDS-PAGE and immunoblotting
The procedure was performed as described [36]. Compa-
rable tissue samples of the apex of the heart have been used
for protein extraction. Quantification of the signal strength
was done by a phosphor-imager (LAS-3000, Fujifilm).
Immunostainings
The procedure was performed as described [36]. Compa-
rable sections from the lateral wall of the heart have been
used for immunostainings.
Confocal microscopy
Analysis of the stained sections was carried out using a
Leica (Leica Microsystems AG, Heerbrugg, Switzerland)
confocal unit (Leica SP 5) equipped with an inverse
microscope. DAPI was excited by a diode laser with 405-
nm excitation, FITC fluorochrome was excited by an argon
laser and Cy-3 and Cy-5 fluorochromes were excited by
helium–neon lasers. Leica PL APO 63x/1.32 NA oil or PL
APO 10x/0.3 NA oil immersion objectives were used.
Image processing was done on a PC workstation using the
image processing software Imaris (Bitplane AG, Zurich,
Switzerland) and Photoshop (Adobe Systems, San Jose,
USA).
RT-qPCR
Total RNA was isolated from comparable tissue samples of
mouse or human tissues using TRIZOL Reagent (Invitrogen
AG, Basel, Switzerland) or the RNeasy kit (Qiagen AG,
Hombrechtikon, Switzerland). Reverse transcription was
carried out on approximately 1 lg total RNA, cDNA was
produced with the Thermoscript RT-PCR System (Invitro-
gen, Basel, Switzerland) and amplified using TAQ-poly-
merase (BioTherm DNA Polymerase; GeneCraft GmbH,
Lu¨dinghausen, Germany). qPCR was performed using iTaq
SYBR Green Supermix from Bio-Rad (Reinach, Switzer-
land) and a LightCycler 480 from Roche (Basel, Switzer-
land). Relative quantification of RNA levels was calculated
by the DDct method [33]. Primers used for the amplification
of the fragments of mouse or human myomesin, M-protein
and myomesin-3 were derived from the corresponding
sequences [myomesin: Ensembl gene Myom1, ENSMUS
G00000024049 (mouse), ENSG00000101605 (human);
M-protein: Ensembl gene Myom2, ID ENSMUSG000
00031461 (mouse), ENSG00000036448 (human); myome-
sin-3: Ensembl gene Myom3, ENSMUSG00000037139
(mouse), ENSG00000142661 (human)]. Sarcomeric alpha-
actinin: Ensembl gene Actn2 ENSMUSG00000052374
(mouse) and ENSG00000077522 (human) and beta-actin:
Ensembl gene Actb, ENSG00000075624 (human) have been
used for normalization. For primer sequences, see Supple-
mentary Table S1.
Human samples and patient demographics
The study was approved by an institutional ethics com-
mittee and has been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki. Informed consent has been obtained from all
patients included in this study. 40 tissue samples (ven-
tricular and atrial) were obtained from 25 patients (16
male, 9 female) who underwent heart surgery. Patients
were Caucasians, aged 30–62 years (plus a 0.5-year-old
baby) and suffered from idiopathic (with unknown etio-
logy) DCM (N = 13) or served as controls (N = 12).
Control samples (non-dilated) were obtained from patients
with hypertrophic cardiomyopathy (HCM) (N = 7) or from
patients who either underwent adult cardiac surgery
(N = 3) or congenital heart surgery (N = 2). Heart biop-
sies were obtained from two groups of DCM patients. The
first group was classified as end-stage heart-failure (NYHA
III–IV) and underwent only heart transplantation [N = 10,
EF = 12.7 ± 1.9%], while the second group was sup-
ported by a left ventricular assist device (LVAD) for a
certain period of time before heart transplantation (N = 3).
All samples were processed in liquid nitrogen immediately
after harvesting.
Patients in the control group received the standard
medication such as aspirin, statins and beta-blockers. In
addition, patients who have had valve replacement or
repair received warfarin either lifelong or for a certain
period of time. Patients who underwent congenital heart
surgery mainly did not take any relevant medications. In
contrast to this, HCM and DCM patients being in heart
failure received standard heart failure medication including
ACE inhibitors, beta-blockers, calcium channel inhibitors
as well as diuretics.
Statistics
All data were considered as normally distributed and ana-
lyzed by unpaired, two-tailed Student’s t test and for
multiple comparisons, by one-way or two-way ANOVA.
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Table 1 Echocardiography data (5 weeks)
Wild type (N = 6) b-Catenin cDex3 (N = 6) MLP-KO (N = 6)
Age (days) 35 ± 0 35 ± 0 35 ± 0
Female/male ratio 4/2 3/3 3/3
Body weight (g) 15.5 ± 2.9 15.6 ± 2.8 14.3 ± 1.3
Heart rate (beats/min) 394 ± 46 372 ± 42 413 ± 29
LVPW;d (mm) 0.58 ± 0.03 0.72 ± 0.08* 0.72 ± 0.06*
LVPW;s (mm) 0.78 ± 0.04 0.87 ± 0.10* 0.83 ± 0.05
IVS;s (mm) 0.78 ± 0.03 0.79 ± 0.08 0.83 ± 0.06
LVID;d (mm) 3.39 ± 0.37 3.75 ± 0.42 3.90 ± 0.11*
LVID;s (mm) 2.31 ± 0.29 2.79 ± 0.49* 2.99 ± 0.10*
LV Vol;d (ll) 47.6 ± 12.4 60.8 ± 15.1 65.8 ± 4.7*
LV Vol;s (ll) 18.6 ± 5.6 30.5 ± 12.3 34.6 ± 2.9*
EF (%) 61.2 ± 3.0 51.5 ± 9.2* 47.3 ± 3.0*
FS (%) 31.9 ± 2.0 26.0 ± 5.5* 23.4 ± 1.8*
Ejection time (s) 57.3 ± 4.6 54.6 ± 4.5 53.0 ± 3.1
MV E/A 1.79 ± 0.36 2.23 ± 1.10 1.69 ± 0.54
Mean VcFc (circ/s) 0.56 ± 0.05 0.48 ± 0.12 0.44 ± 0.06*
LV mass (mg) 47.4 ± 8.7 69.7 ± 18.4* 74.9 ± 5.6*
LV mass/body weight (mg/g) 3.06 ± 0.37 4.47 ± 1.18* 5.24 ± 0.39*
Cardiac function and ventricular dimensions of 5-week-old b-catenin cDex3 and MLP-KO mice assessed by transthoracic echocardiography
LVPW left ventricular free wall, IVS interventricular septum, LVID left ventricular internal diameter, FS fractional shortening, MV E/A mitral
valve E:A velocity ratio, VcFc circumferential fiber shortening, d diastole, s systole
* Significant differences compared to wild type
Table 2 Echocardiography data (4 months)
Wild type (N = 9) b-Catenin cDex3 (N = 9) MLP-KO (N = 6)
Age (days) 124 ± 5 125 ± 5 139 ± 4
Female/male ratio 4/5 6/3 4/2
Body weight (g) 28.1 ± 3.5 24.2 ± 2.9* 24.9 ± 2.0
Heart rate (beats/min) 397 ± 34 421 ± 52 360 ± 25
LVPW;d (mm) 0.73 ± 0.07 0.76 ± 0.09 0.71 ± 0.04
LVPW;s (mm) 0.98 ± 0.07 0.85 ± 0.10* 0.86 ± 0.11*
IVS;s (mm) 0.89 ± 0.03 0.88 ± 0.07 0.79 ± 0.03*
LVID;d (mm) 4.09 ± 0.11 5.07 ± 0.64* 4.64 ± 0.18*
LVID;s (mm) 2.86 ± 0.11 4.33 ± 0.73* 3.69 ± 0.24*
LV Vol;d (ll) 73.9 ± 4.5 124.7 ± 34.9* 99.5 ± 9.2*
LV Vol;s (ll) 31.0 ± 2.9 87.5 ± 32.2* 58.1 ± 8.8*
EF (%) 58.02 ± 3.32 31.65 ± 8.23* 41.66 ± 6.5*
FS (%) 30.3 ± 2.3 15.1 ± 4.2* 20.5 ± 3.7*
Ejection time (s) 54.9 ± 2.9 47.4 ± 4.5* 54.2 ± 2.9
MV E/A 1.94 ± 0.62 4.84 ± 3.37* 4.01 ± 1.43*
Mean VcFc (circ/s) 0.55 ± 0.05 0.31 ± 0.06* 0.38 ± 0.08*
LV mass (mg) 81.5 ± 8.0 134.5 ± 40.1* 97.2 ± 9.3*
LV mass/body weight (mg/g) 2.92 ± 0.29 5.62 ± 1.75* 3.91 ± 0.36*
Cardiac function and ventricular dimensions of 4-month-old b-catenin cDex3 and MLP-KO mice assessed by transthoracic echocardiography
LVPW left ventricular free wall, IVS interventricular septum, LVID left ventricular internal diameter, FS fractional shortening, MV E/A mitral
valve E:A velocity ratio, VcFc circumferential fiber shortening, d diastole, s systole
* Significant differences compared to wild type
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Differences were considered as statistically significant for
P \ 0.05.
Results
Characterization of disease progression in transgenic
mouse models for DCM by echocardiography
To evaluate the expression level of the myomesin genes in
pathological situations in general, heart samples of mouse
models for HCM or DCM were examined by RT-PCR
analysis (Figure S1, supplementary material). These
experiments showed that alterations in M-band composi-
tion are a hallmark of DCM compared to HCM models or
controls.
Motivated by this finding, we analyzed the disease pro-
gression in detail, using two transgenic mouse models which
progressively develop a severe DCM: the MLP-KO mouse
[5] and a mouse with stabilized b-catenin in the heart
(b-catenin cDex3) [19]. Several parameters describing the
pump function and dimensions of the heart were measured
at the age of 2 weeks, 5 weeks (Table 1), 2 months and
4 months (Table 2) in both mouse models and controls. The
diastolic volume of the left ventricle (LV) was clearly
enlarged in both models at the age of 4 months verifying the
DCM phenotype (Fig. 2a). The hearts of MLP-KO and
b-catenin cDex3 mice showed a significant reduction of the
ejection fraction (EF) already at the age of 5 weeks which
was even more pronounced at a higher age (Fig. 2b), dem-
onstrating a continuous deterioration of cardiac function
during disease progression. Both mouse models have
chamber dilation with reduced wall motion, which was more
pronounced in the b-catenin cDex3 mice at the age of
4 months (Fig. 2c).
Alterations in expression of myomesin proteins
during the development of DCM
To investigate whether alterations in the protein composi-
tion of the sarcomeric M-band can be used as biomarker for
processes occurring in diseased heart, we analyzed the
Fig. 2 Echocardiography of DCM models. a Left ventricular
diastolic volume measurements confirming the DCM phenotype in
MLP-KO (black) and more severe in b-catenin cDex3 animals (gray)
compared to controls (white). b Ejection fraction of control (white),
b-catenin cDex3 (gray) and MLP-KO (black) mice demonstrating
the continuous decrease in heart function during progression of the
disease. Error bars represent standard deviation, N C 6 for each
subgroup. Asterisks mean significant differences compared to control
groups. c M-mode echocardiographic tracings in control (left),
b-catenin cDex3 mice (center) and MLP-KO (right) at the age of
4 months. Left ventricular dimensions are indicated by white lines
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accumulation of myomesin proteins in DCM mouse mod-
els. Protein levels in the left ventricle of MLP-KO and
b-catenin cDex3 were measured by Western blot at different
time points and compared to controls. These experiments
showed a significant up-regulation of EH-myomesin
already at the early stage of DCM in MLP-KO mice
(2 weeks), whereas in the b-catenin cDex3 mice the up-
regulation does not start before 5 weeks of age (Fig. 3b). At
the age of 4 months, EH-myomesin level is significantly
higher in both DCM models by a factor of about two. There
is a relatively high variability in the accumulation of EH-
myomesin between individual animals (Fig. 3a, EH). At the
age of 2 months, M-protein is down-regulated in both DCM
models, but more prominent in the MLP KO mouse
(Fig. 3a, M-pr). Interestingly, an up-regulation of myome-
sin-3 can be detected only in the MLP-KO mice (Fig. 3a,
Myo3), which is consistent with the RT-PCR analysis
(Figure S1). In addition, b-catenin is clearly accumulated in
both mouse models (Fig. 3a, b-cat), in accordance with
previous studies, reporting the up-regulation of adherens
junction protein components in dilated heart [31]. To con-
firm that the up-regulation of EH-myomesin in the heart is a
general phenomenon of mouse DCM models, two addi-
tional models have been analyzed by Western blot (Sup-
plementary Table S2). In addition, a non-genetic mouse
model for heart failure (ischemic cardiomyopathy due to
chronic left anterior descending artery ligation [27]) was
analyzed and showed up-regulation of EH-myomesin in the
scar region of the myocardial infarct, where the ventricular
wall is very thin (Supplementary Figure S2).
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Fig. 3 Expression of myomesin proteins during development of
dilated cardiomyopathy. a Immunoblot analysis of mouse heart
protein extracts of control, b-catenin cDex3 mice and MLP-KO mice
(age 2 months). EH-myomesin (EH) is accumulated in several
animals suffering from DCM with variability between individual
mice. A slight down-regulation of M-protein is detectable in the b-
catenin cDex3 mice, which is more pronounced in the MLP-KO mice
at the age of 2 months (M-pr). Myomesin-3 up-regulation is
detectable only in the MLP-KO mice (Myo3). b-Catenin (b-cat) is
accumulated in both mouse models, with the b-catenin cDex3 mice
showing expression of the truncated form (lower bands) in addition to
the normal protein (upper bands). b Quantification of EH-myomesin
levels during disease development shows an accumulation already at
2 weeks in the MLP-KO mice (black columns). In the b-catenin
cDex3 model (gray columns) a significant up-regulation of this
isoform is detectable at the age of 8 weeks. At 4 months, both DCM
models show an accumulation of EH-myomesin. Expression levels
are normalized on sarcomeric actin levels and compared to control
mice. Error bars represent standard deviation, N C 6 for each
subgroup. Asterisks mean significant differences compared to control
groups. P values compared to control were as follows: 2 weeks (b-
catenin cDex3, P = 0.163; MLP KO, P = 0.007), 5 weeks (b-catenin
cDex3, P = 0.089; MLP KO, P = 0.001), 2 months (b-catenin cDex3,
P = 0.016; MLP KO, P = 0.067), 4 months (b-catenin cDex3,
P = 0.016; MLP KO, P = 0.041). w weeks, m months
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Accumulation of EH-myomesin correlates with dilation
and impairment of heart function
To analyze the potential of EH-myomesin up-regulation as
a marker for DCM and to investigate its role in disease
development, protein levels of this isoform were compared
to cardiac parameters measured by echocardiography.
Already at the age of 5 weeks, there was a strong corre-
lation between the left ventricular (LV) systolic volume
and EH-myomesin accumulation (correlation coefficient
R = 0.82, Fig. 4a). At this age, all MLP-KO mice suffer
from a significant dilation including EH-myomesin up-
regulation, whereas the b-catenin cDex3 animals show a
relatively wide variation in LV systolic volume. Further-
more, the ejection fraction was measured and compared
with the accumulation of EH-myomesin (Fig. 4b). At the
age of 5 weeks, two out of six b-catenin cDex3 animals
still had a normal heart function with an ejection fraction
around 60% and normal levels of the EH-myomesin iso-
form. However, four out of six of the b-catenin cDex3
animals had a significantly reduced ejection fraction
compared to controls and showed up-regulation of this
protein. The coefficient R = -0.86 highlighted the
strong negative correlation between ejection fraction and
EH-myomesin accumulation. The correlation coefficients
between EH-myomesin and the cardiac parameters LV
systolic volume, LV systolic internal diameter and ejection
fraction were compared at different stages of the disease
(Fig. 4c). The strongest correlations were found at the age
of 5 weeks and were slightly reduced at later stages of the
disease.
EH-myomesin is up-regulated in cardiomyocytes
of mouse DCM models in a cell-specific fashion
The expression of EH-myomesin and M-protein was ana-
lyzed at the cellular level by immunofluorescence analysis
of mouse heart cryosections (age 4 months, Fig. 5). In
dilated hearts, these proteins changed their expression in a
cell-specific manner: EH-myomesin is accumulated in both
DCM models with certain heterogeneity, whereas M-pro-
tein is slightly down-regulated.
The b-catenin cDex3 mouse progressively develops
severe DCM and dies at the latest of 6 months. To
evaluate the expression of M-band components at the
end-stage of DCM in more detail, b-catenin cDex3 mice
were analyzed at the age of 5 months and compared
to MLP-KO and control mice (Fig. 6). In these hearts,
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Fig. 4 Comparison of EH-myomesin expression with heart param-
eters. a Left ventricular (LV) volume in systole measured by
echocardiography at the age of 5 weeks correlates with EH-myomesin
expression in MLP-KO (oblique squares, N = 6) and b-catenin
cDex3 mice (triangles, N = 6). The b-catenin cDex3 transgenic
animals show a relatively wide distribution in volume, whereas the
MLP-KO mice have a significant dilation including up-regulation of
EH-myomesin expression already at this age. The strong correlation
between LV volume and EH-myomesin accumulation is reflected by a
correlation coefficient of R = 0.82. Control mice are shown as
squares (N = 6). b At the age of 5 weeks, the controls (squares) and
some of the b-catenin cDex3 animals (triangles) have a normal
ejection fraction (about 60%) including normal levels of EH-
myomesin. Animals with a clearly reduced ejection fraction have
accumulated this protein significantly. The strong negative correlation
is reflected by a correlation coefficient R = -0.86. c Table showing
the correlation coefficients for the relations between EH-myomesin
protein levels and LV systolic volume (LV Volume, s), LV systolic
internal diameter (LVID, s) or % ejection fraction (EF%). The
strongest correlations were found at the age of 5 weeks. 5w 5 weeks,
2m 2 months, 4m 4 months
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EH-myomesin expression showed considerable heteroge-
neity with a complete switch to an embryonic phenotype
in some cardiomyocytes (Fig. 6, asterisk in b, e, h).
M-protein was significantly down-regulated in both DCM
models compared to controls (Fig. 6d–f). This down-
regulation is rather homogenous in the MLP-KO,
whereas in the b-catenin cDex3 animals it was patchy in
respect to single cardiomyocytes. b-Catenin (Fig. 6k–m,
red in a–c) was up-regulated in both DCM models, as
described [12].
Up-regulation of EH-myomesin in human DCM
patients
To check the expression of the myomesin isoforms in the
heart of humans suffering from cardiomyopathy, RT-qPCR
analysis was carried out using total RNA isolated from
heart biopsies of patients suffering from DCM and com-
pared to non-dilated control hearts. Myomesin was
expressed evenly (Figure S3), whereas the EH-myomesin
isoform was significantly up-regulated in the hearts of most
Fig. 5 Heterogeneous
accumulation of EH-myomesin
in cardiomyocytes of mouse
DCM models. Cryosections of
mouse heart ventricles of
control (a, d, g, k, n), b-catenin
cDex3 (b, e, h, l, o) and MLP
KO (c, f, i, m, p) mice at the age
of 4 months quadruple-stained
with antibodies against
M-protein (d–f; green in
overlays), EH-myomesin
(g–i; blue in overlays), DAPI
(k–m; red in overlays) and
N-cadherin (n–p). A down-
regulation of M-protein is
apparent in single
cardiomyocytes of the b-catenin
cDex3 transgenic animals. In
contrast, M-protein is relatively
homogenously expressed in
MLP KO (f) and control mice
(d). EH-myomesin is
accumulated in both DCM
models (h, i; blue in b, c) with
certain heterogeneity. In the
b-catenin cDex3 transgenic
animals, the same
cardiomyocytes, which show an
up-regulation of EH-myomesin
(h), have reduced levels of
M-protein (e), leading to a more
embryonic-like phenotype. A
big accumulation of nuclei can
be detected in the hearts of
b-catenin cDex3 mice (l, red in
overlay), including fibrosis
(regions without M-band
staining) and some
hypertrophied nuclei. The
accumulation of the intercalated
disk component N-cadherin
(n–p) is visible in both DCM
mouse models. Scale bar
100 lm
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patients suffering from DCM compared to non-dilated
controls and to patients suffering from HCM, with con-
siderable variability in the expression levels (Fig. 7, Fig.
S4). No significant accumulation of EH-myomesin could
be detected in hearts of patients treated by a LVAD. In
DCM patients without LVAD, the up-regulation of EH-
myomesin was 41 times compared to controls. The corre-
lation coefficient between % ejection fraction and the
expression level of EH-myomesin was R = -0.64, con-
firming the correlation in the transgenic DCM mouse
models. In all patients with an ejection fraction below 20%,
EH-myomesin levels were up-regulated at least 10 times
compared to control patients. We have found no indication
that medication affected the expression of EH-myomesin.
Furthermore, stainings of cryosections of human hearts
were performed to confirm the re-expression of EH-
myomesin in human DCM patients (Fig. 8, right) compared to
a healthy control (Fig. 8, left). The sections were triple
stained with antibodies against M-protein, EH-myomesin,
and b-catenin. M-protein was homogenously expressed in
both hearts, whereas EH-myomesin was re-expressed in
single cardiomyocytes of the DCM patients. These results
were consistent with the data obtained from mouse DCM
models.
Myomesin-3 is expressed in human skeletal muscle
and adult heart
To analyze whether the myomesin genes were expressed in
a tissue-specific manner also in human, RT-PCR analysis
was performed on total RNA isolated from different human
tissues (Figure S5). The muscle tissue samples were tested
with primers specific for different myomesins (Table S1).
Myomesin was detectable in all types of human-striated
muscle, whereas EH-myomesin was found in the embryo-
nic heart. M-protein was highly expressed in embryonic
Fig. 6 Expression of M-band
components at the end-stage of
DCM. Cryosections of mouse
heart ventricles of control (a, d,
g, k), b-catenin cDex3 (b, e, h,
l) and MLP-KO (c, f, i, m) mice
at the age of 5 months triple-
stained with antibodies against
M-protein (d–f; green in
overlays), EH-myomesin (g–i;
blue in overlays), and b-catenin
(k–m; red in overlays).
M-protein is homogenously
expressed in control mice (d),
whereas in b-catenin cDex3
(e) and MLP-KO (f) transgenic
animals it is significantly down-
regulated. This down-regulation
is homogenous in the MLP-KO,
whereas in the b-catenin cDex3
animals it is extremely
heterogeneous. EH-myomesin is
up-regulated extremely
heterogeneously in the
b-catenin cDex3 transgenic
animals. Some single
cardiomyocytes show a switch
to an embryonic phenotype of
M-bands, with higher level of
EH-myomesin expression and
very low M-protein expression
level (asterisk in e, h).
b-Catenin is strongly
accumulated in both DCM
models (l, m; red in b, c).
Scale bar 20 lm
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skeletal muscle and adult heart of human. In contrast to
mouse, myomesin-3 was detectable not only in skeletal
muscle, but also in the adult human myocardium.
Discussion
Previous studies described the M-band as a dynamic ele-
ment of the sarcomeric cytoskeleton which adapts to the
contractile regime of a particular muscle by varying the
type and number of different myomesin molecules cross-
linking the thick filaments [3]. Here, we characterize the
M-band protein composition in mouse and human heart, in
both healthy and pathological situations. We show that
expression patterns of myomesins correlate with the
physiological parameters of the heart muscle, and vary
depending on species, developmental stage or type of
cardiomyopathy (Tables 3, 4).
The M-band protein composition is identical in embry-
onic heart of mouse and human and is restricted to the
EH-myomesin isoform. However, this isoform is down-
regulated around birth and the adult hearts show distinct
expression patterns of myomesins (Table 3). Human
myocardium accumulates much more myomesin-3 com-
pared to mouse heart. Thus, the M-band composition of
mouse heart resembles fast skeletal fibers, while that in
human heart is more close to intermediate speed fibers
[36]. This can be explained by different physiological
demands to the M-bands. The mouse heart beats much
faster than the human one, and the mouse heart myosin
produces much higher contraction speed [7]. Both param-
eters probably necessitate the presence of a ‘‘faster’’
M-band in mouse myocardium. Our observations showed
the limitations in direct applicability of results obtained
from mouse models for the human heart. The differences in
physiological characteristics and in the cytoskeletal design
between mouse and human hearts should always be taken
into account by any prediction.
Our experiments showed an accumulation of EH-
myomesin in both mouse models of DCM (MLP-KO and
b-catenin cDex3), which correlated well with the decrease
of ejection fraction at the early stage of disease. This
suggests EH-myomesin as an early marker of DCM. In
addition to EH-myomesin up-regulation, we found that
some DCM mouse models (e.g. MLP-KO mice) up-regu-
lated myomesin-3 expression, which might represent a
fine-tuning of the M-band to specific biomechanical alter-
ations. As discussed above, the adult human heart has a
different M-band composition compared to mouse. How-
ever, the up-regulation of EH-myomesin was a constant
characteristic also of DCM in human heart, irrespective of
the cause of the disease. We found that expression of EH-
myomesin is dramatically up-regulated (41-fold, P \ 0.001)
in the DCM group compared to the control and HCM groups.
The up-regulation of EH-myomesin was much lower in DCM
hearts supported by a LVAD.
The up-regulation of EH-myomesin in DCM is consis-
tent with the reported re-expression of fetal isoforms of
sarcomeric proteins in the dilated heart [10]. Accordingly,
the appearance of the myomesin isoform containing the
additional elastic EH-fragment matches the up-regulation
of compliant titin isoforms in human DCM [26, 29], sug-
gestive of a correlative adaptation of both cytoskeletal
structures in this pathological situation.
What might be the reason for such a remodeling of the
sarcomere cytoskeleton? We propose that it is a general
adaptation to the altered contractile mechanics of the sar-
comere in the dilated heart. Indeed, our observations show
that up-regulation of EH-myomesin is universal for all
tested DCM hearts, irrespectively of species and regardless
to the cause of the disease. Also, the increase of the EH-
myomesin expression correlates well with the decrease of
the heart pumping function and correspondingly to the
increase of volume overload in the dilated heart. Previ-
ously, EH-myomesin expression was reported in fibers
working in the eccentric contraction regime in mouse
skeletal [4] and rat extraocular muscles [39]. The sarco-
mere in the dilated heart has to contract in overstretched
conditions as well, requiring the switch to a ‘‘fuzzy sar-
comere’’ design, which is more stable in eccentric condi-
tions [2]. The application of LVAD leads to a decreased
load of the contracting sarcomere, which correlates with
EH-myomesin (fold upregulation)
90 p < 0.001
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Fig. 7 EH-myomesin is re-expressed in human patients suffering
from DCM. RT-qPCR analysis of human patients suffering from
DCM or HCM using primers specific for EH-myomesin. This isoform
is massively up-regulated (41 times) in the hearts of patients suffering
from DCM (right column, N = 10) compared to non-dilated control
hearts (N = 5) and hearts of patients suffering from HCM (N = 7).
DCM patients under treatment with a left ventricular assist device
(LVAD, N = 3) show no significant re-expression of the EH-
myomesin isoform. Sarcomeric a-actinin was used for normalization.
HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy,
LVAD left ventricular assist device. Error bars represent standard
deviation. Asterisk means significant difference compared to the other
tested groups
Basic Res Cardiol (2011) 106:233–247 243
123
much lower levels of EH-myomesin in the LVAD sup-
ported hearts.
The remodeling to a more embryonic type of cytoskele-
ton might also be an adaptive response to calcium signaling
defects in the failing heart. Indeed, the failing human
heart shows slower relaxation kinetics caused by delayed
Ca2? re-uptake [8] due to reduced SERCA function,
enhanced NCX function, and greater Ca2? leak from the
Fig. 8 EH-myomesin is up-
regulated in the heart of human
DCM patients in cell-specific
fashion. Confocal images of
cryosections of human hearts of
control (a, c, e, g) and a DCM
patient (left ventricle; b, d, f, h)
triple-stained with antibodies
against M-protein (c, d; green in
overlays), EH-myomesin (e, f;
blue in overlays), and with
b-catenin (g, h; red in overlay).
M-protein is homogenously
expressed in both hearts (c, d),
whereas EH-myomesin is up-
regulated in the DCM patient in
a cell-specific manner. Scale
bar 10 lm
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sarcoplasmic reticulum [6]. In the embryonic heart, the
Ca2? re-uptake is compromised by immature excitation–
contraction coupling [11]. The LVAD support improves
the contractility of the failing heart and shortens the rate of
the Ca2? decay to the level of non-failing heart [8]. This
correlates with our finding that EH-myomesin expression
in LVAD supported hearts does not differ significantly
from the non-dilated control hearts.
We have found that the M-band composition changes in
a cell-autonomous fashion in the failing heart. In the heart
of b-catenin cDex3 mice, some cardiomyocytes switch
completely to the embryonic M-band phenotype by up-
regulating EH-myomesin and down-regulating M-protein,
whereas others keep the phenotype of adult cardiomyo-
cytes with high levels of M-protein and very low levels of
EH-myomesin. The down-regulation of M-protein is not
detectable in the human DCM hearts, but EH-myomesin is
also up-regulated in a cell-specific manner. We intend that
increased myocardial strain in dilated heart might provoke
the up-regulation of EH-myomesin and ‘‘patchy’’, cell-
specific expression pattern might be caused by a different
mechanical burden on certain myocytes. This suggestion is
supported by the observation that a strong up-regulation of
EH-myomesin is observed in the scar region of the heart
remodeled after myocardial infarction, as the ventricular
wall is very thin in the scar region and the slim layer of
remaining myocytes is subjected to huge contractile stress.
This is a very important observation, because all molecular
alterations found by previous studies in the diseased
myocardium were averaged values for the whole heart and
did not consider the divergence between individual
cardiomyocytes. We, therefore, hypothesize that M-band
alterations might be part of a general adaptation of the
sarcomeric cytoskeleton to unfavorable working conditions
in the failing heart, and might also affect the mechanical
properties of the cardiomyocytes. The progressive cell-to-
cell heterogeneity through the myocardial wall would
impair the force transmission and might have important
implications for the mechanism of cardiac failure.
Computer models showed that occurrence of mechanical
non-uniformities in myocardial muscle might lead to
spontaneous Ca2? release from sarcoplasmic reticulum and
initiate arrhythmogenic waves [37]. Thus, the cytoskeletal
alterations by DCM, initially driven by a compensatory
mechanism, may eventually become maladaptive with
disease progression. However, further studies are needed to
clarify the role of cytoskeletal non-uniformities in the
development of arrhythmias in the failing heart.
Here, we present for the first time that EH-myomesin,
the dominant myomesin isoform in the embryonic heart, is
up-regulated in DCM. Since we have previously shown
that this myomesin isoform is associated with a higher
degree of M-band elasticity [35], this finding might give
new insights into the understanding of progressive ven-
tricular dilation on a structural level. Furthermore, the
up-regulation of EH-myomesin at early stages of the dis-
ease and its correlation to the impairment of ventricular
function may be used for a better characterization of DCM
in human patients.
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